CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 62 enrolled
Drug / intervention
Occipital Nerve Blockdrug
Likely dose
Bupivacaine via occipital nerve block (specific dose not stated)AI-extracted
Key inclusion· 4
  • Pregnant patient with confirmed live intrauterine pregnancy
  • Acute headache complaint
  • Headache pain severity at least 4 on visual rating scale
  • Presenting to Maternal Evaluation Unit at UAB hospital
Key exclusion· 10
  • Systolic BP ≥140 or diastolic BP ≥90 with 1+ protein on urine dipstick (preeclampsia)
  • Systolic BP ≥160 or diastolic BP ≥105
  • Focal neurological symptoms
  • Altered level of consciousness or disorientation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03951649
NCT03951649Phase 4Completed

Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial

University of Alabama at Birmingham·interventional·Posted May 15, 2019·Updated Dec 20, 2023

In Brief

A Phase 4 clinical trial evaluating Occipital Nerve Block for Headache and 2 related conditions. Completed, enrolled 62 participants across 1 site.

Detailed Summary

This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMay 15, 2019
Enrollment StartFeb 10, 2020
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.1 years ago

Interventions

Occipital Nerve Blockdrug

This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.